Table 2 Targeted antibodies for lung cancer therapy
From: Lung cancer immunotherapy: progress, pitfalls, and promises
Targeted Antibodies | Lung cancer type | Related Molecule | Target / Bioactivity |
|---|---|---|---|
Monoclonal Antibodies (MABs) | NSCLC | Cetuximab | Anti-EGFR |
Necitumumab | Anti-EGFR | ||
Nimotuzumab | Anti-EGFR | ||
Ficlatuzumab | Anti-EGFR | ||
Bevacizumab | Anti-VEGF | ||
Ramucirumab | Anti-VEGF/VEGFR2 | ||
Nivolumab | Anti-PD-1 | ||
Pembrolizumab | Anti-PD-1 | ||
Ipilimumab | Anti-CTLA-4 | ||
Tremelimumab | Anti-CTLA-4 | ||
Denosumab | Anti-RANKL | ||
Figitumumab | Anti-IGF-1R | ||
SCLC | Tarextumab | Anti-Notch2 / Notch3 | |
Tucotuzumab | Anti-EpCAM | ||
Bec2 | Anti-GD3 | ||
Antibody–Drug Conjugate (ADC) | SCLC | Rovalpituzumab tesirine | Anti-DLL3 |
Sacituzumab govitecan | Anti-Trop-2 | ||
Lorvotuzumab mertansine | Anti-CD56 | ||
NSCLC | Ado-Trastuzumab emtansine | Anti-HER2 | |
Telisotuzumab vedotin | Anti-cMET | ||
Enapotamab vedotin | Anti-AXL | ||
Bispecific antibodies | NSCLC | Amivantamab | Anti-EGFR, Anti-MET |